Eli N. Perencevich

Eli N. Perencevich

Auto-generated profile, based on publicly available information

Eli N. Perencevich

Center for Access & Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System , Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SCSara E. Cosgrove
Sara E. Cosgrove
GSGeorge Sakoulas
George Sakoulas
EPEli N. Perencevich
Eli N. Perencevich
MSMitchell J. Schwaber
Mitchell J. Schwaber
AKAdolf W. Karchmer
Adolf W. Karchmer
YCYehuda Carmeli
Yehuda Carmeli
A meta-analysis was performed to summarize the impact of methicillin-resistance on mortality in Staphylococcus aureus bacteremia. A search of the MED

1 January 2006 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
AHAnthony D. Harris
Anthony D. Harris
JMJessina C. McGregor
Jessina C. McGregor
EPEli N. Perencevich
Eli N. Perencevich
JFJon P. Furuno
Jon P. Furuno
JZJingkun Zhu
Jingkun Zhu
JFJoseph Finkelstein
Joseph Finkelstein
Quasi-experimental study designs, often described as nonrandomized, pre-post intervention studies, are common in the medical informatics literature.

1 September 2011 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
DMDaniel J Morgan
Daniel J Morgan
IOIruka N Okeke
Iruka N Okeke
RLRamanan Laxminarayan
Ramanan Laxminarayan
EPEli N Perencevich
Eli N Perencevich
SWScott Weisenberg
Scott Weisenberg

1 February 2003 in Emerging Infectious Diseases
Verified
Journal Article
Open access
EPEli N. Perencevich
Eli N. Perencevich
KSKenneth E. Sands
Kenneth E. Sands
SCSara E. Cosgrove
Sara E. Cosgrove
EGEdward Guadagnoli
Edward Guadagnoli
EMEllen Meara
Ellen Meara
RPRichard Platt
Richard Platt
Although surgical site infections (SSIs) are known to cause substantial illness and costs during the index hospitalization, little information exists about the impact of infections diagnosed after discharge, which constitute the majority of SSIs. In this study, using patient questionnaire and administrative databases, we assessed the clinical outcomes and resource utilization in the 8-week postoperative period associated with SSIs recognized after discharge. SSI recognized after discharge was confirmed in 89 (1.9%) of 4,571 procedures from May 1997 to October 1998. Patients with SSI, but not controls, had a significant decline in SF-12 (Medical Outcomes Study 12-Item Short-Form Health Survey) mental health component scores after surgery (p=0.004). Patients required significantly more outpatient visits, emergency room visits, radiology services, readmissions, and home health aide services than did controls. Average total costs during the 8 weeks after discharge were US$5,155 for patients with SSI and $1,773 for controls (p<0.001).

1 March 2009 in American Journal of Infection Control
Verified
Journal Article
Closed access
DMDaniel J. Morgan
Daniel J. Morgan
DDDaniel J. Diekema
Daniel J. Diekema
KSKent Sepkowitz
Kent Sepkowitz
EPEli N. Perencevich
Eli N. Perencevich

1 October 2008 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
LMLisa L Maragakis
Lisa L Maragakis
EPEli N Perencevich
Eli N Perencevich
SCSara E Cosgrove
Sara E Cosgrove
Knowledge of the clinical and economic impact of antimicrobial resistance is useful to influence programs and behavior in healthcare facilities, to guide policy makers and funding agencies, to define the prognosis of individual patients and to stimulate interest in developing new antimicrobial agents and therapies. There are a variety of important issues that must be considered when designing or interpreting studies into the clinical and economic outcomes associated with antimicrobial resistance. One of the most misunderstood issues is how to measure cost appropriately. Although imperfect, existing data show that there is an association between antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and increases in mortality, morbidity, length of hospitalization and cost of healthcare. Patients with infections due to antimicrobial-resistant organisms have higher costs (US $6,000-30,000) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Given limited budgets, knowledge of the clinical and economic impact of antibiotic-resistant bacterial infections, coupled with the benefits of specific interventions targeted to reduce these infections, will allow for optimal control and improved patient safety. In this review, the authors discuss a variety of important issues that must be considered when designing or interpreting studies of the clinical and economic outcomes associated with antimicrobial resistance. Representative literature is reviewed regarding the associations between antimicrobial resistance in specific pathogens and adverse outcomes, including increased mortality, length of hospital stay and cost.